1. Home
  2. MCHX vs IMA Comparison

MCHX vs IMA Comparison

Compare MCHX & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

N/A

Current Price

$1.81

Market Cap

67.3M

ML Signal

N/A

IMA

ImageneBio Inc.

HOLD

Current Price

$5.33

Market Cap

66.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
IMA
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.3M
66.3M
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
MCHX
IMA
Price
$1.81
$5.33
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
19.2K
8.9K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,291,000.00
$800,000.00
Revenue This Year
$5.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.32
$3.94
52 Week High
$2.04
$13.98

Technical Indicators

Market Signals
Indicator
MCHX
IMA
Relative Strength Index (RSI) 57.05 40.34
Support Level $1.54 $3.94
Resistance Level $1.95 $6.11
Average True Range (ATR) 0.08 0.31
MACD -0.00 -0.03
Stochastic Oscillator 51.87 2.29

Price Performance

Historical Comparison
MCHX
IMA

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: